Knight Therapeutics Inc. (TSE:GUD) Insider Sime Armoyan Sells 15,000 Shares

Knight Therapeutics Inc. (TSE:GUD) insider Sime Armoyan sold 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 7th. The stock was sold at an average price of C$5.95, for a total value of C$89,250.00.

Sime Armoyan also recently made the following trade(s):

• On Thursday, April 11th, Sime Armoyan sold 10,900 shares of Knight Therapeutics stock. The stock was sold at an average price of C$5.95, for a total transaction of C$64,855.00.
• On Monday, April 1st, Sime Armoyan bought 6,200 shares of Knight Therapeutics stock. The shares were acquired at an average cost of C$5.25 per share, with a total value of C$32,550.00.
• On Monday, March 25th, Sime Armoyan purchased 351,000 shares of Knight Therapeutics stock. The stock was acquired at an average cost of C$5.25 per share, for a total transaction of C$1,842,750.00.

Knight Therapeutics Trading Up 0.9 %

TSE:GUD opened at C$5.92 on Thursday. Knight Therapeutics Inc. has a 12 month low of C$4.35 and a 12 month high of C$5.95. The company has a current ratio of 3.20, a quick ratio of 1.79 and a debt-to-equity ratio of 9.25. The firm’s 50 day moving average is C$5.56 and its 200 day moving average is C$5.37. The stock has a market capitalization of C$598.93 million, a PE ratio of -37.00, a price-to-earnings-growth ratio of -1,013.50 and a beta of 0.49.

Knight Therapeutics (TSE:GUD) last issued its earnings results on Thursday, March 21st. The company reported C($0.03) earnings per share (EPS) for the quarter, missing the consensus estimate of C$0.02 by C($0.05). The firm had revenue of C$74.20 million during the quarter, compared to the consensus estimate of C$78.37 million. Knight Therapeutics had a negative net margin of 5.13% and a negative return on equity of 2.14%. Sell-side analysts expect that Knight Therapeutics Inc. will post 0.0602815 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on GUD. Royal Bank of Canada increased their price target on Knight Therapeutics from C$6.50 to C$7.00 and gave the company an “outperform” rating in a research report on Friday, March 22nd. Raymond James lifted their price target on Knight Therapeutics from C$7.00 to C$7.50 and gave the stock an “outperform” rating in a report on Wednesday, March 6th. Finally, Stifel Nicolaus raised their target price on Knight Therapeutics from C$5.25 to C$5.40 and gave the company a “hold” rating in a research report on Wednesday, May 1st.

About Knight Therapeutics

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.